BG
SGMO

BlackRock Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

BlackRock Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$135K Buy
44,406
+2,667
+6% +$9.71K ﹤0.01% 2767
2016
Q3 		$193K Buy
41,739
+1,143
+3% +$5.81K ﹤0.01% 2640
2016
Q2 		$235K Sell
40,596
-26,360
-39% -$168K ﹤0.01% 2523
2016
Q1 		$405K Buy
66,956
+9,095
+16% +$54.6K ﹤0.01% 2320
2015
Q4 		$529K Sell
57,861
-509
-0.9% -$3.92K ﹤0.01% 2175
2015
Q3 		$329K Buy
58,370
+29,865
+105% +$246K ﹤0.01% 2367
2015
Q2 		$316K Buy
28,505
+3,175
+13% +$40.9K ﹤0.01% 2438
2015
Q1 		$397K Buy
25,330
+16,532
+188% +$256K ﹤0.01% 2280
2014
Q4 		$134K Buy
8,798
+889
+11% +$10.8K ﹤0.01% 2611
2014
Q3 		$85K Sell
7,909
-254
-3% -$3.32K ﹤0.01% 2609
2014
Q2 		$124K Sell
8,163
-568
-7% -$8.17K ﹤0.01% 2557
2014
Q1 		$158K Buy
8,731
+5,504
+171% +$106K ﹤0.01% 2505
2013
Q4 		$45K Buy
+3,227
New +$37.2K ﹤0.01% 2564

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

BlackRock Group's SGMO Position: Q4 2016 in Review

BlackRock Group increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 6.4% in Q4 2016, buying an estimated $9.71K and bringing the position to 44,406 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #2767.

BlackRock Group first reported a position in SGMO in Q4 2013 and has held it in 13 quarters since. The position peaked at $529K in Q4 2015. 126 funds tracked by Wall St. Rank hold SGMO as of Q4 2016.

  • BlackRock Group held 44,406 shares of SANGAMO THERAPEUTICS INC worth $135K as of Q4 2016.
  • BlackRock Group bought 2,667 SANGAMO THERAPEUTICS INC shares in Q4 2016, an estimated $9.71K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2767 holding.
  • BlackRock Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and has held it in 13 quarters since.
  • BlackRock Group's SANGAMO THERAPEUTICS INC position peaked at $529K in Q4 2015.
  • 126 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.